GigaGen
  • Our Company
    • Team
    • News
  • Our Science
    • Surge and Magnify Technologies
    • Publications, Scientific Posters & Presentations
  • Pipeline
    • Oncology
    • Recombinant Polyclonals
  • Careers
  • Contact
  • Menu Menu

News Archive

BioSpace: 6 Award-Winning Life Science Companies in the Bay Area

04/19/2019

There are numerous ways to rank a company as “the best place to work.” Some listings rank companies by pay, others by how “happy and engaged” the workforce is, others by culture and benefits. Some rankings use metrics while others are based on employee surveys. Here’s a look at six San Francisco Bay Area life […]

Read more

GigaGen Publishes Study in Peer-Reviewed Journal mAbs, Validating Feasibility and Benefit of Rapid Parallel Immunization Protocols for Discovery of Novel Monoclonal Antibodies

03/25/2019

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the publication of a study that shows the feasibility and benefit of its Surge™ antibody discovery and engineering platform for rapid monoclonal antibody discovery using multiple immunization protocols in parallel. The study has been published online in the peer-reviewed scientific journal mAbs, and it […]

Read more

STAT: GigaGen CEO Dave Johnson, PhD, discusses why biotech execs need to create an environment that fosters a truly scientific culture

03/13/2019

“What traditions do you want to follow for your baby?” asked the midwife leading our prenatal education group. As we went around the circle of parents-to-be, most couples discussed holiday traditions, camping trips, and weekend routines. When it was my turn to share, I thought about the pseudoscience that had been espoused in this group […]

Read more

GigaGen CEO David Johnson to Present on Surge Technology at 2019 Antibody Engineering & Therapeutics Asia Meeting

02/25/2019

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., chief executive officer, will present at the 2019 Antibody Engineering & Therapeutics Asia Meeting. Dr. Johnson will also co-chair the presentation, which will take place at 8:45 a.m. JST on February 26, 2019, at the Hilton Tokyo Bay Hotel in […]

Read more

GigaGen Publishes Study Demonstrating Optimal Method for Selecting OX40 Therapeutic Candidates from Antibody Repertoires

02/20/2019

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the publication of a study showing how it adapted its Surge™ antibody discovery and engineering platform to improve selection of OX40 agonists. The study has been published online in the peer-reviewed scientific journal, Antibodies, as part of the special issue Antibody Repertoire Mining for […]

Read more

GigaGen Promotes Adam Adler, Ph.D., to Chief Scientific Officer

01/30/2019

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the promotion of Adam Adler, Ph.D., to Chief Scientific Officer (CSO). Previously, Dr. Adler was the company’s Vice President of Research and Development. In addition, Gigagen has promoted Rena Mizrahi, Ph.D to Vice President of Process Development and Catherine Medina to Vice President of […]

Read more

GigaGen Announces Appointment of Erica Stone, Ph.D., as Director, Immuno-Oncology

01/10/2019

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that Erica Stone, Ph.D., has joined the company as director, immuno-oncology. “We welcome award-winning immunologist Dr. Stone to the GigaGen team,” said Dave Johnson, Ph.D., CEO of GigaGen. “Dr. Stone brings with her a deep understanding of the tumor microenvironment and checkpoint inhibitors that […]

Read more

GigaGen CEO David Johnson to Present at 2018 Antibody Engineering & Therapeutics Meeting

12/07/2018

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., chief executive officer, will present at the 2018 Antibody Engineering & Therapeutics Meeting. Dr. Johnson’s presentation will take place at 3:15 p.m. PST on December 9, 2018, at the Manchester Grand Hyatt in San Diego, Calif. Read the full press […]

Read more

GigaGen CEO David Johnson to Present on Development of Recombinant Polyclonal Therapies for Infectious Disease at 10th Annual PEGS Summit Europe

11/12/2018

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., Founder and Chief Executive Officer, will present on the development of highly diverse, functional antibodies for infectious disease utilizing Surge technology at the 10th Annual Protein & Antibody Engineering Summit (PEGS) in Europe. Dr. Johnson’s invited podium presentation is titled […]

Read more

GigaGen to Present Data on Immuno-Oncology Pipeline at the Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting

11/09/2018

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced a data presentation at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer (SITC). Adam Adler, Ph.D., Vice President of Research and Development, will present on the antibody drug candidates discovered by the company’s industry-leading Surge technology against 17 unique immuno-oncology targets. […]

Read more

Genetic Engineering & Biotechnology News: Microfluidic dragnet catches most-wanted antibodies – GigaGen exhaustively interrogates antibodies to find drug candidates

11/02/2018

“Scrappy.” That’s a one-word summation of GigaGen’s approach to both the business and science of biotech. “When you’re a new company, you have to be scrappy and clever. When I founded GigaGen in 2011, I didn’t have a big war chest of money, so I had to find a way to be competitive. That’s central […]

Read more

GigaGen to Present Data on Recombinant Hyperimmune Gammaglobulin at the 18th Biennial Meeting of the European Society for Immunodeficiencies

10/26/2018

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced a data presentation at the 18th Biennial Meeting of the European Society for Immunodeficiencies (ESID). Rena Mizrahi, Ph.D., director of protein engineering, will present on the company’s proprietary recombinant hyperimmune gammaglobulin program. The conference takes place October 24-27, 2018, at the Centro de Congressos […]

Read more

Drug Discovery News: GigaGen CEO Dave Johnson, PhD, discusses I/O product development and impact of NIH grant support on company growth

08/14/2018

The National Institutes of Health (NIH) is a household name in the drug discovery and development industry. Among the NIH’s many recipients is South San Francisco, Calif.-based GigaGen, a biotherapeutics company. GigaGen’s CEO, Dr. Dave Johnson, took some time to talk with us about how NIH funding and participation in the I-Corps commercialization program helped […]

Read more

GigaGen CEO Dave Johnson on Biotech Nation Radio – Ep. 18-31

08/03/2018

Listen to Moira Gunn’s interview with GigaGen CEO Dave Johnson, PhD, on developing next generation I/O drugs to fight cancer on  Biotech Nation Radio

Read more

Drug Development and Delivery: GigaGen CEO Dave Johnson discusses Why Understanding Immune Dysregulation is the Key to Drug Development

06/06/2018

Antibodies have been used since the late 1980s as therapies to treat serious diseases, and demand is soaring to new heights today. However, conventional antibody drug discovery technologies are labor-intensive and slow. Pharmaceutical companies select drug candidates from just a small fraction of the antibodies that exist in a natural immune repertoire and have limited […]

Read more

GigaGen Announces Appointment of Sheila M. Keating, Ph.D., as Director, Immunology

05/03/2018

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that Sheila M. Keating, Ph.D., has joined the company as Director, Immunology. Dr. Keating will lead clinical development of GigaGen’s recombinant hyperimmune gammaglobulin product in collaboration with pharmaceutical partner Grifols.  Read the full press release.  

Read more

GigaGen CEO David Johnson to Present on the Power of Surge Technology to Discover Unique Immuno-oncology Antibodies at 14th Annual PEGS Summit

04/30/2018

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., Founder and Chief Executive Officer, will present on the discovery of unique and functional antibodies utilizing Surge technology at the 14th Annual PEGS Summit. Dr. Johnson’s invited podium presentation is titled “Discovery of High-Affinity Human PD-1 and LAG-3 Antibodies Using […]

Read more

GigaGen CEO David Johnson to Present Data from Surge Platform at American Association for Cancer Research Annual Meeting 2018

04/09/2018

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., chief executive officer, will present data from the company’s proprietary Surge platform at the American Association for Cancer Research (AACR) Annual Meeting 2018. The conference will take place April 14-18, 2018, at the McCormick Place in Chicago. Read the full […]

Read more

Nature Biotechnology: GigaGen Recognized as One of the Top Biotech Startups Funded in 2017

04/06/2018

Our annual survey highlights how immune-oncology and screens based on the application of cutting-edge omics technologies are providing a launchpad for a succession of startups interrogating biology across biomedicine. Read the full story.

Read more

GigaGen Presents Methods for Rapid Immuno-Oncology Antibody Discovery at 2018 Keystone Symposia on Antibodies as Drugs

02/27/2018

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, presented preclinical research on its industry-leading Surge™ technology at the 2018 Keystone Symposia on Antibodies as Drugs: Translating Molecules into Treatments. In its research, GigaGen used Surge, a high-throughput single cell droplet microfluidic technology, to rapidly discover high-affinity, fully human antibody drug candidates against 17 immuno-oncology […]

Read more
Page 3 of 512345

Latest Tweets

GigaGen Follow

Billions of immune cells in your bloodstream fight disease on a daily basis. GigaGen turns these cells into life-saving medical therapies.

gigageninc
GigaGen @gigageninc ·
21 Jun

Polyclonal #AntibodyTherapies contain a variety of antibody types and are ideal for diseases that comprise many targets. We’re developing the first #RecombinantPolyclonal antibody therapies for the treatment of infectious diseases. Learn more: https://bit.ly/38xUi5Z

Reply on Twitter 1539231952494116864 Retweet on Twitter 1539231952494116864 Like on Twitter 1539231952494116864 1 Twitter 1539231952494116864
GigaGen @gigageninc ·
14 Jun

On #WorldBloodDonorDay today, we thank all the blood and #plasma donors worldwide who help to provide a source of lifesaving therapies, including #antibody therapies for patients with #InfectiousDiseases.

Reply on Twitter 1536695417592758273 Retweet on Twitter 1536695417592758273 2 Like on Twitter 1536695417592758273 2 Twitter 1536695417592758273
GigaGen @gigageninc ·
7 Jun

This month, we’re proud to support @CancerResearch’s #CancerImmunotherapyMonth and contribute to developing safer and more effective #immunotherapies for patients in need. Learn about how you can support cancer immunotherapy research this month: https://bit.ly/3MHetgg

Reply on Twitter 1534218665415122944 Retweet on Twitter 1534218665415122944 Like on Twitter 1534218665415122944 Twitter 1534218665415122944
GigaGen @gigageninc ·
27 May

We’re advancing the first recombinant #polyclonal #antibody products to treat patients with #InfectiousDiseases and #immunodeficiencies. Learn more about our work and approach: https://bit.ly/3fTeXj1

Reply on Twitter 1530172179752570880 Retweet on Twitter 1530172179752570880 2 Like on Twitter 1530172179752570880 1 Twitter 1530172179752570880
GigaGen @gigageninc ·
19 May

We are happy to announce the publication of our latest peer-reviewed research article demonstrating the potential of our machine learning platform to improve antibody drug discovery and development. Learn more in our press release here: https://bit.ly/3MpERvb

Reply on Twitter 1527341245416165393 Retweet on Twitter 1527341245416165393 1 Like on Twitter 1527341245416165393 2 Twitter 1527341245416165393
©Copyright 2022 GigaGen. All Rights Reserved. | Privacy Policy | Terms | Disclaimer
  • Twitter
  • LinkedIn
Scroll to top